Ally Financial Inc. Reduces Stock Position in AbbVie Inc. $ABBV

Ally Financial Inc. trimmed its stake in AbbVie Inc. (NYSE:ABBV - Free Report) by 33.3% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 18,000 shares of the company's stock after selling 9,000 shares during the period. Ally Financial Inc.'s holdings in AbbVie were worth $4,113,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently modified their holdings of ABBV. Chelsea Counsel Co. purchased a new stake in shares of AbbVie in the 3rd quarter worth about $26,000. Litman Gregory Wealth Management LLC purchased a new stake in shares of AbbVie in the 4th quarter worth about $28,000. Westend Capital Management LLC purchased a new stake in shares of AbbVie in the 4th quarter worth about $29,000. Texas Capital Bancshares Inc TX purchased a new stake in shares of AbbVie in the 3rd quarter worth about $31,000. Finally, Legacy Wealth Managment LLC ID lifted its position in shares of AbbVie by 115.9% in the 4th quarter. Legacy Wealth Managment LLC ID now owns 136 shares of the company's stock worth $31,000 after purchasing an additional 73 shares during the period. 70.23% of the stock is owned by hedge funds and other institutional investors.

AbbVie News Summary

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie said nine-year CLL14 data showed venetoclax plus obinutuzumab delivered durable progression-free survival in previously untreated chronic lymphocytic leukemia, strengthening the case for the drug’s long-term commercial value. AbbVie Presents New Data at EHA 2026 Congress for VENCLEXTA®/VENCLYXTO® (venetoclax) in First-Line Chronic Lymphocytic Leukemia Highlighting Long-Term Treatment Outcomes for Patients: Nine-Year Results
• Positive Sentiment: Investors are also focused on AbbVie’s broader pipeline and franchise strength, with commentary pointing to Skyrizi and Rinvoq continuing to drive revenue growth, which supports the company’s outlook beyond legacy Humira. Will Skyrizi & Rinvoq Continue to Drive AbbVie's Topline Through 2026?
• Neutral Sentiment: Several market commentaries described AbbVie as a defensive, high-quality compounder, but noted the shares may not be cheap at current levels, which suggests valuation may temper upside even with strong fundamentals. AbbVie: A Defensive Compounder Worth Holding, But Not A Bargain Buy
• Negative Sentiment: One article highlighted regulatory risk around AbbVie’s fast-acting neurotoxin TrenibotE after an FDA complete response letter, which could delay a potential growth driver if development setbacks persist. FDA Issues Complete Response Letter for AbbVie’s Fast-Acting Neurotoxin TrenibotE; Spokane dermatologist Dr. Philip Werschler on What the Letter Means

AbbVie Stock Performance

NYSE:ABBV opened at $227.54 on Friday. The firm has a market cap of $402.02 billion, a P/E ratio of 112.09, a P/E/G ratio of 0.70 and a beta of 0.32. AbbVie Inc. has a fifty-two week low of $181.73 and a fifty-two week high of $244.81. The firm has a 50-day simple moving average of $211.05 and a two-hundred day simple moving average of $219.07.

AbbVie (NYSE:ABBV - Get Free Report) last announced its quarterly earnings results on Wednesday, April 29th. The company reported $2.65 EPS for the quarter, topping analysts' consensus estimates of $2.59 by $0.06. AbbVie had a net margin of 5.79% and a negative return on equity of 576.45%. The firm had revenue of $15 billion during the quarter, compared to analyst estimates of $14.72 billion. During the same period in the previous year, the business posted $2.46 earnings per share. The business's revenue for the quarter was up 12.4% on a year-over-year basis. On average, equities research analysts predict that AbbVie Inc. will post 14.3 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on the stock. William Blair reissued an "outperform" rating on shares of AbbVie in a research report on Monday, March 9th. Weiss Ratings reissued a "hold (c)" rating on shares of AbbVie in a research report on Monday, June 8th. Royal Bank Of Canada assumed coverage on shares of AbbVie in a research report on Tuesday, February 24th. They set an "outperform" rating and a $260.00 price target for the company. Wall Street Zen cut shares of AbbVie from a "strong-buy" rating to a "buy" rating in a research report on Sunday, June 7th. Finally, Piper Sandler lifted their price target on shares of AbbVie from $294.00 to $298.00 and gave the company an "overweight" rating in a research report on Thursday, May 14th. Three equities research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and six have given a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $253.43.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie's product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women's health.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.